Introduction
In the United States, only 250-300 cases of retinoblastoma are diagnosed each year. 1 Patients with hereditary retinoblastoma, representing approximately 40% of patients, have germline mutations in the retinoblastoma gene, RB1, and frequently have bilateral or multifocal unilateral tumors. 2 Due to improvements in diagnosis and treatment, patients with hereditary retinoblastoma are living into adulthood, and secondary malignancies are now the most common cause of death. [3] [4] [5] [6] [7] Radiation therapy for hereditary retinoblastoma has been identified as a causative factor in the development of subsequent malignancies. 3, 5, 7 The most common secondary malignancies reported include sarcoma, carcinoma, intracranial primitive neuroectodermal tumor, and melanoma. 5 Breast, lung, and bladder carcinomas have been identified as the most frequent
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Malignant phyllodes with hereditary retinoblastoma 2 secondary epithelial malignancies. 6 Phyllodes tumors of the breast are uncommon, representing less than 1% of breast tumors. 8 The occurrence of phyllodes tumor of the breast in the setting of retinoblastoma has only been reported in two patients. 12 We report a case of malignant phyllodes tumor of the breast occurring in a patient with a history of hereditary retinoblastoma as an infant and leiomyosarcoma of the nasal cavity as a young adult. The imaging findings of phyllodes tumors and the association between these neoplasms are reviewed.
Case Report
The patient was diagnosed with hereditary bilateral retinoblastoma and treated with radiation therapy at four months of age. She then developed a leiomyosarcoma of the nasal cavity at age 29 (Figs. 1 & 2) , which was diagnosed on excisional biopsy. She subsequently had a recurrence of the leiomyosarcoma treated with surgery at 30 years of age. The patient was never treated with chemotherapy and no radiation therapy was given for her nasal leiomyosarcoma before diagnosis of phyllodes. The differential diagnosis for the imaging findings included mammary carcinoma, fibroadenoma, and phyllodes tumor. A BIRADS 4 assessment was given and ultrasound-guided biopsy recommended. A second small 10 mm oval circumscribed isodense mass was also noted on mammogram and ultrasound at the 6:00 position. This mass was determined to be probably benign, a BIRADS 3 assessment given and a 6 month follow-up mammogram was recommended.
The patient's physician preferred that both lesions be biopsied. Subsequently, the patient developed a second recurrence of the nasal leiomyosarcoma at the age of 33. She was treated surgically and is currently receiving external beam radiation therapy.
Discussion
Phyllodes tumors are uncommon breast tumors that frequently present as rapidly enlarging palpable masses. They average 3-6 cm in size at presentation, although tumor sizes from 1 cm to over 20 cm have been reported. Liberman et al. reported that tumors 3 cm or greater were significantly more likely to be malignant. 13 Mammography typically demonstrates a large, round to oval, high density mass with circumscribed and lobulated margins.
Sonography usually demonstrates a lobulated, welldefined, heterogeneous, hypoechoic mass without posterior acoustic shadowing.
14 There may be internal cystic spaces. 13 
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approximately 3-19% of patients. Sentinel lymph node biopsy or axillary dissection is not routinely performed, unless clinically indicated. There is no role for adjuvant chemotherapy, radiation therapy or hormonal therapy in the treatment of primary phyllodes tumor. Chemotherapy and radiation therapy may be considered on a case by case basis in the setting of recurrence or metastases. The survival rate of malignant phyllodes is much higher than nonphyllodes breast cancer. There is no data regarding differences in prognosis or management of malignant phyllodes in patients with or without retinoblastoma.
Retinoblastoma occurs in both sporadic (somatic mutation) and familial (germinal mutation) forms. Knudson's "two hit" hypothesis to explain retinoblastoma tumorigenesis requires two complementary chromosomal mutations. 17 In the familial form of retinoblastoma, the 'first hit" is a germline mutation followed by a somatic mutation of the remaining wild-type copy. These individuals are thus more susceptible to second non-ocular tumors because every cell in the body carries the germline mutation.
The retinoblastoma susceptibility gene RB1, located on the long (q) arm of chromosome 13 at position 14.2, functions as a tumor suppressor gene. The protein encoded by RB1, known as retinoblastoma protein or pRB, is vital to numerous cell processes, including DNA repair, cell cycle control, DNA replication, and proliferation. 18 Cells with two altered copies of the RB1 gene produce no functional pRB and are unable to regulate cell division effectively.
It is well known that hereditary retinoblastoma patients are susceptible to a wide variety of second malignancies, particularly soft tissue sarcomas in the setting of prior radiotherapy. [3] [4] [5] [6] [7] Phyllodes tumors of the breast, however, are uncommonly reported as secondary tumors in these patients.
12 Recent investigation has identified several chromosomal regions where amplifications, gains and losses were present in phyllodes tumors. 19 In particular, gains of 1q and losses of 13q are hallmark alterations in borderline and malignant phyllodes tumors. Likewise, losses of 13q are identified in approximately 70% of leiomyosarcomas.
20
Similar to phyllodes tumor, gains at 1q are identified in 50% of cases of retinoblastoma.
21
The shared chromosomal alterations in these three tumor types suggest common genetic and cell signaling pathways that are altered and are in need of further study. Clinically, these patients are at high risk for developing a variety of malignancies in multiple sites, and thus close surveillance is necessary. 
Conclusion

